• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Merck KGaA Establishes U.S. Generic Pharmaceuticals Unit

Posted on: Monday, 8 August 2005, 06:00 CDT

Merck KGaA announced today that it has established a generic pharmaceuticals business, Genpharm, L.P., in New York to provide direct access to customers in the United States.

"This will increase Merck's presence in the world's largest pharmaceutical market and will help solidify our position as the world's third-largest global generics company," said Hank Klakurka, CEO of the Merck Generics Group, a wholly owned business of Merck KGaA in Darmstadt, Germany.

Robert J. Mauro was named President of Genpharm, L.P. effective July 18, 2005, and will report directly to Klakurka. Mauro will be responsible for Merck's generics business in the United States excluding the operations of Dey Inc., Merck's Napa, California-based subsidiary that specializes in value-added respiratory treatments.

Mauro has more than 25 years of pharmaceutical experience in executive management functions in the U.S., most recently as president and chief operating officer of Able Laboratories Inc., New Jersey.

Merck is a global pharmaceutical and chemical company with sales of EUR 5.9 billion in 2004, a history that began in 1668, and a future shaped by 28,600 employees in 54 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 73% interest and free shareholders own the remaining 27%. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917.

Source: Business Wire

More News in this Category